IMV (IMVIF) Osake Kurssi

IMV, Inc. is a clinical-stage biopharmaceutical company, which engage in providing a novel class of cancer immunotherapies and vaccines against infectious diseases including COVID-19. The company is headquartered in Dartmouth, Nova Scotia and currently employs 63 full-time employees. The company went IPO on 2018-06-01. The firm is focused on developing a class of cancer vaccines based on DPX, an immune-educating technology platform, which is designed to inform a specific anti-tumor immune response, offering benefit to patients with solid or hematological cancers. Its therapeutic candidate, maveropepimut-S (MVP-S) is a DPX-based cancer vaccine that delivers antigenic peptides from survivin, a cancer antigen commonly overexpressed in advanced cancers. MVP-S also delivers an innate immune activator and a universal CD4 T cell helper peptide. MVP-S is administered in low doses approximately once every two months, which drives a persistent immune attack on tumor cells. MVP-S is being evaluated in Phase IIB clinical trials for advanced r/r Diffuse Large B Cell Lymphoma (DLBCL) and platinum resistant ovarian cancer. The firm is also developing a dual-targeted cancer vaccine candidate leveraging the DPX delivery platform, DPX-SurMAGE.